Risk assessment in the management of patients with ocular hypertension.
about
Citicoline: A Food Beneficial for Patients Suffering from or Threated with GlaucomaThe Role of the IL-20 Subfamily in GlaucomaEffect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopyCochlin and glaucoma: a mini-review.Morpho-functional follow-up of the optic nerve in treated ocular hypertension: disc morphometry and steady-state pattern electroretinogram.A new method for determining physician decision thresholds using empiric, uncertain recommendations.Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota.Economic impact of primary open-angle glaucoma in Australia.Retinal transcriptome profiling at transcription start sites: a cap analysis of gene expression early after axonal injury.RNA sequence reveals mouse retinal transcriptome changes early after axonal injury.Why Do People (Still) Go Blind from Glaucoma?An assessment of the health and economic burdens of glaucomaA randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER studyStructure/Function relationship and retinal ganglion cells counts to discriminate glaucomatous damages.Long-term results of viscocanalostomy and phacoviscocanalostomy: a twelve-year follow-up study.Using perimetric data to estimate ganglion cell loss for detecting progression of glaucoma: a comparison of models.The future of glaucoma clinics.Causal models in primary open angle glaucoma.Evaluation of the significance of some diagnostic parameters in making an early diagnose of primary open-angle glaucomaBilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the ratSpectral analysis of intraocular pressure pulse wave in ocular hypertensive and primary open angle glaucoma patientsProgress toward personalized medicine for glaucomaFrequency Doubling Technology vs Standard Automated Perimetry in Ocular Hypertensive Patients.Intraocular Pressure: Does it Measure Up?Criteria for choosing clinically effective glaucoma treatment: A discussion panel consensus.Protocol-driven adjustment of ocular hypotensive medication in patients at low risk of conversion to glaucoma.Imaging apoptosis in the eye.Machine Learning Techniques in Clinical Vision Sciences.Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.Localized Changes in Retinal Nerve Fiber Layer Thickness as a Predictor of Localized Functional Change in Glaucoma.Evaluation of lamina cribrosa thickness and depth in ocular hypertension.The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.Sensitivity and specificity for detecting early glaucoma in eyes with high myopia from normative database of macular ganglion cell complex thickness obtained from normal non-myopic or highly myopic Asian eyes.Diagnostic capability of Pulsar perimetry in pre-perimetric and early glaucoma.Risk assessment for glaucoma.Reproducibility of Central Corneal Thickness Measurements in Healthy and Glaucomatous Eyes.Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye.Lamina Cribrosa Morphology Predicts Progressive Retinal Nerve Fiber Layer Loss In Eyes with Suspected Glaucoma.Preperimetric Glaucoma Prospective Study (PPGPS): Predicting Visual Field Progression With Basal Optic Nerve Head Blood Flow in Normotensive PPG Eyes.
P2860
Q26752575-418E9069-CAA6-42A2-A52B-1FAE5655B7B1Q26768258-531CBC32-57F8-4866-8FA1-421C1519397CQ28220559-0DA290C1-9014-48E7-A20A-0E73D0CB5C15Q30499664-8558BB29-EFB1-469A-8C49-708E29ACFF22Q33359419-7F170F81-454C-4A53-870F-54F686FDB82BQ33551018-4B2EEEA4-6D1F-4923-A670-B22ADC19CF88Q33685328-2553B7B5-E687-45D2-9B39-0BB9B3357AD8Q33918990-2AA68C70-44DA-4473-9FFB-39715EB21C84Q34582221-3F39C7D8-587E-4635-9033-12E8DC966566Q35133718-9DB56E25-574E-4149-ABEA-90241298E088Q35160642-032CDC70-4B42-4D50-8FD6-762B48F36308Q35506935-D8830CD1-BE18-4111-B09F-CC95F236AB94Q35677641-90583F5C-F061-42E4-B540-51CDCF04DEC3Q35880097-996DCEA7-A97E-4E1C-B305-38B0F1C539FFQ36297021-3B181B2E-E8B3-4853-99AE-DA24D5D9993CQ36355986-9708F70E-AB32-4970-9A37-5EDB541CD8B3Q36452434-92A0D6CD-508C-4470-9186-E296E276B2BBQ36551151-D1C37113-4F9C-425D-B5E1-78FFFB4CBD6EQ36577519-CB2F244C-1DA7-4A2A-B2B6-9520CFD867C9Q36599983-F29FFB70-BA5E-4F52-BDC3-2ECCF1862B83Q36851244-F5BBD945-6166-4CB7-8FB1-EF44B894B346Q37058798-B30F0879-C5F1-4673-B51C-AD3923DDA6AAQ37239853-13FFF365-7D56-4D50-B52E-54E92D811929Q37378983-3D56C351-225B-4938-89F8-F770FA930F53Q37667460-2E3E3BDE-9A58-4B53-9653-CFA4C2311936Q38367081-A072F670-C6B9-4E9B-921B-E1296BF6B334Q38375518-3FFB4017-7941-46F1-95DB-45AC8683030BQ38881742-8F59CA73-ED00-468E-A84E-23976D006311Q38934012-B84BE056-8AF2-49F4-B541-7D10EB2575BBQ38988955-EF332620-A0B3-4102-A15B-1A2C90E71D80Q39523978-5FF9221F-F900-4595-A8D4-6E7E9A4E9F7EQ40548319-E00F4D08-BDBC-4A54-BE03-B94BF066DBEEQ41683709-A5838FCE-7DF3-476A-BE44-901B77D6D6DCQ41759242-4C51CB6A-2D60-4823-AE6C-2307A8E06468Q41953991-E31DEE8B-F1C6-4C42-84BD-AA262DE34185Q42578732-ADC50D28-A5D4-4A77-9F5B-535A507B76BCQ45065508-7EC30986-EDB9-4A1A-8341-E217BC155C44Q47129551-B22524A5-5AB2-4CA6-8F58-653B9A523C3DQ47731186-EA56DD3A-0E43-411B-9B61-AF9523675649Q49164858-1F007AF0-1C5D-4E14-B6EA-BA684747F57D
P2860
Risk assessment in the management of patients with ocular hypertension.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Risk assessment in the management of patients with ocular hypertension.
@ast
Risk assessment in the management of patients with ocular hypertension.
@en
type
label
Risk assessment in the management of patients with ocular hypertension.
@ast
Risk assessment in the management of patients with ocular hypertension.
@en
prefLabel
Risk assessment in the management of patients with ocular hypertension.
@ast
Risk assessment in the management of patients with ocular hypertension.
@en
P2093
P1476
Risk assessment in the management of patients with ocular hypertension.
@en
P2093
Anne L Coleman
Christopher A Girkin
David S Friedman
George A Cioffi
Jeffrey M Liebmann
Kuldev Singh
M Roy Wilson
Richard Wilson
Robert D Fechtner
William B Kannel
P304
P356
10.1016/J.AJO.2004.04.054
P407
P577
2004-09-01T00:00:00Z